Comparative efficacy and safety of JAK inhibitor-based strategies in JAK inhibitor-naïve myelofibrosis: A systematic review and network meta-analysis. (PubMed, Ther Adv Hematol) - Oct 10, 2026 - "Momelotinib showed comparable SVR35 (OR = 0.886), while selective JAK2 inhibitors (fedratinib and pacritinib) were numerically inferior in efficacy. Crucially, ruxolitinib remains the benchmark for symptom control and treatment retention in patients with adequate platelets. CRD420261330640."
Journal • Retrospective data • Fibrosis • Hematological Disorders • Immunology • Myelofibrosis • Oncology • Thrombocytopenia • ACVR1 • JAK1
|
|
He Li; Linfeng Li; Ting Niu; Zhongwang Wang
|